Literature DB >> 20373150

Development and validation of a discriminating in vitro dissolution method for a poorly soluble drug, olmesartan medoxomil: comparison between commercial tablets.

Lisiane Bajerski1, Rochele Cassanta Rossi, Carolina Lupi Dias, Ana Maria Bergold, Pedro Eduardo Fröehlich.   

Abstract

A dissolution test for tablets containing 40 mg of olmesartan medoxomil (OLM) was developed and validated using both LC-UV and UV methods. After evaluation of the sink condition, dissolution medium, and stability of the drug, the method was validated using USP apparatus 2, 50 rpm rotation speed, and 900 ml of deaerated H(2)O + 0.5% sodium lauryl sulfate (w/v) at pH 6.8 (adjusted with 18% phosphoric acid) as the dissolution medium. The model-independent method using difference factor (f(1)) and similarity factor (f(2)), model-dependent method, and dissolution efficiency were employed to compare dissolution profiles. The kinetic parameters of drug release were also investigated. The obtained results provided adequate dissolution profiles. The developed dissolution test was validated according to international guidelines. Since there is no monograph for this drug in tablets, the dissolution method presented here can be used as a quality control test for OLM in this dosage form, especially in a batch to batch evaluation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373150      PMCID: PMC2902315          DOI: 10.1208/s12249-010-9421-0

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  6 in total

Review 1.  Modeling and comparison of dissolution profiles.

Authors:  P Costa; J M Sousa Lobo
Journal:  Eur J Pharm Sci       Date:  2001-05       Impact factor: 4.384

2.  Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide.

Authors:  R Löbenberg; J Krämer; V P Shah; G L Amidon; J B Dressman
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

3.  Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.

Authors:  Kazutaka Yoshihara; Yuying Gao; Hiroshi Shiga; D Russell Wada; Masafumi Hisaoka
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences.

Authors:  E Swanepoel; W Liebenberg; B Devarakonda; M M de Villiers
Journal:  Pharmazie       Date:  2003-02       Impact factor: 1.267

5.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

6.  In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants.

Authors:  V P Shah; J J Konecny; R L Everett; B McCullough; A C Noorizadeh; J P Skelly
Journal:  Pharm Res       Date:  1989-07       Impact factor: 4.200

  6 in total
  3 in total

1.  Stability of Olmesartan Medoxomil Extemporaneous Suspensions.

Authors:  Prapanna Bhattarai; Timothy McPherson; Marcelo Nieto; William M Kolling
Journal:  J Pharm Technol       Date:  2021-10-27

2.  Solubilization of beclomethasone dipropionate in sterically stabilized phospholipid nanomicelles (SSMs): physicochemical and in vitro evaluations.

Authors:  Mohanad Naji Sahib; Shaymaa Abdalwahed Abdulameer; Yusrida Darwis; Kok Khiang Peh; Yvonne Tze Fung Tan
Journal:  Drug Des Devel Ther       Date:  2012       Impact factor: 4.162

3.  Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment.

Authors:  Rofida Albash; Mohamed A El-Nabarawi; Hanan Refai; Aly A Abdelbary
Journal:  Int J Nanomedicine       Date:  2019-08-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.